Quick answers
- What is Acitretin used for?
- The FDA-approved label (Acitretin, Sigmapharm Laboratories, LLC, August 5, 2026) says: “Acitretin Capsules, USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, Acitretin Capsules, USP should be prescribed only by those knowledgeable in the systemic use of retinoids. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Acitretin have a boxed warning?
- Yes. The FDA label for Acitretin has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Acitretin?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Acitretin been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Acitretin?
- 8 companies list prescription products of Acitretin in the FDA NDC Directory, including Amneal Pharmaceuticals of New York LLC, Teva Pharmaceuticals USA, Inc. and AvKARE.
What Acitretin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Acitretin Capsules, USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, Acitretin Capsules, USP should be prescribed only by those knowledgeable in the systemic use of retinoids. …
— FDA label: Acitretin, Sigmapharm Laboratories, LLC, effective August 5, 2026. Read the full label on DailyMed →
The FDA has 9 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
8 of 9 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule |
|---|---|
| Route | Oral |
| Prescription products | 24 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| acitretin 10 mg capsule | Generic | $2.79 per capsule |
| acitretin 17.5 mg capsule | Generic | $4.50 per capsule |
| acitretin 25 mg capsule | Generic | $3.51 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Amneal Pharmaceuticals of New York LLC4 products
- Teva Pharmaceuticals USA, Inc.3 products
- AvKARE3 products
- Sigmapharm Laboratories, LLC3 products
- Alembic Pharmaceuticals Limited3 products
- Alembic Pharmaceuticals Inc.3 products
- Bryant Ranch Prepack3 products
- Mylan Pharmaceuticals Inc.2 products
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (6)
- ANDA091455Barr Labs Inc · April 4, 2013
- ANDA202897Teva Pharms USA · April 4, 2013
- ANDA204633Sigmapharm Labs LLC · May 22, 2015
- ANDA202148Mylan · September 10, 2015
- ANDA202552Impax Labs Inc · December 23, 2015
- ANDA217774Alembic · August 5, 2024
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 199689, 199690, 894859, 894863 |
|---|---|
| SPL set ID of the quoted label | a6546625-acb8-460e-b34e-f795bfb3680a |
| FDA labels (SPL) | 9 |
| FDA applications | 6 ANDA |
| Active ingredients (FDA) | ACITRETIN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Acitretin, Sigmapharm Laboratories, LLC, effective August 5, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →